Kimberly Westrich, MA, of Cencora, explains how US payers' views and uses of value assessment tools have evolved.
In an interview at AMCP Nexus 2023 in Orlando, Florida, Kimberly Westrich, MA, of Cencora, explained the evolution of US payers’ views and uses of value assessment tools. Westrich was also a speaker during the session “Optimizing Value Assessment Tools for Coverage and Reimbursement Decisions: Promises and Pitfalls” on October 18, where she discussed the topic at length.
At Cencora, Westrich is a director of the value and access strategy team, where she leads projects relating to value assessment frameworks, specifically focusing on US markets and appraisals conducted by the Institute for Clinical and Economic Review (ICER).
Transcript
How have US payers' views and uses of value assessment tools evolved?
One of the things that we do at Cencora, we have a managed care network panel, which is a panel of US payers, and we talk to them regularly about important issues. Value assessment is something that we've been talking to the panel about since 2016.
Interestingly enough, familiarity with value assessments has increased from 2016 to 2018 to 2020. It's something that's been steadily growing, but their use has actually stabilized. When we look at the data, there was a big jump in use between 2016 and 2018, and this is when frameworks were really developing and starting to mature, but it's really stabilized since 2018.
What does that stabilization look like? ICER, the Institute for Clinical and Economic Review, is one of the most prevalent and most well-known value assessment frameworks, and we have 8 in 10 payers that are saying yes, we use ICER assessments to help inform our coverage and reimbursement decisions. Similar numbers say that they use ICER frameworks to inform their pricing negotiations.
Some interesting context to put that into context is that while we have all of these payers that are using ICER reports—they're a great compilation of all of the evidence that's out there—payers tell us that ICER reports are only 1 piece of information that they use in the world of value assessment. Specialty society guidelines were the highest source of valuable information in our survey, higher than ICER. Other things that were useful sources of information include AMCP [Academy of Managed Care Pharmacy] dossiers, some payers use international health technology assessment information, some payers use information that comes from PCORI, the Patient-Centered Outcomes Research Institute. So while payers are using ICER, it's only 1 piece of information that they're using in the broader universe.
A second thing that I want to say about ICER context is that ICER only does about 8 to 10 assessments each year. If you think about the FDA, it approves about 50 drugs per year, so there's only information from ICER that's available for really a subset of the new treatments each year. While payers can use it and it helps inform their decisions, it's only 1 piece of a broader group of information that they're using, and it's only available for a very small subset of the decisions that they're making each year.
Bringing Connectivity to the Specialty Pharmacy Workflow
May 2nd 2024In a session during the final full day of conference activity at AXS24, experts from CVS Health and Surescripts emphasized the need to simplify the prescribing workflow for specialty medication through proactive messaging, automation, and interoperability.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Industry Experts Tackle Specialty Drug Access Challenges for Employer Benefit Plans
May 2nd 2024Representatives from ICON plc and Symphony Health joined forces at AXS24 to discuss the challenges of managing high-cost specialty drugs and how they influence self-funded employer benefit plan design and employee access to specialty medications.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More